Immutep Ltd has released a press release.
Prima Enters New MTA with CYTLIMIC
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from Immutep
- Prima announces new LAG-3 agonist antibody product candidate
- Prima announces TACTI-mel clinical trial data
- Prima announces AIPAC clinical trial data
- Prima receives UK approval for AIPAC study
- Wuxi & Prima sign MOU for strategic partnership
Later from Immutep
- Prima commences recruitment for 2nd cohort of melanoma trial
- PRR commences randomised phase IIb clinical trial
- French Research Tax Credit Payment Received
- US patent granted for IMP321
- PRR completes recruitment for 2nd patient cohort
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep